Krystal Biotech (KRYS) Restructuring Costs (2022 - 2024)

Krystal Biotech (KRYS) posted quarterly Restructuring Costs of $12.5 million for Q3 2024, down 66.67% on a QoQ basis from $37.5 million in Q2 2024.

Krystal Biotech (KRYS) Restructuring Costs (2022 - 2024) Analysis & Trends

Krystal Biotech has reported Restructuring Costs for 3 years, with the latest figure at $12.5 million in Q3 2024.

Restructuring Costs for Q3 2024 came in at $12.5 million, changed N/A year-over-year; the trailing twelve-month figure through Jun 2025 was $12.5 million (down 88.89% YoY), and the FY2024 annual result was $37.5 million, up 200.0% from the prior year.
Restructuring Costs declined to $12.5 million in Q3 2024, from $37.5 million in the prior quarter.
Over five years, Restructuring Costs peaked at $37.5 million in Q4 2023 and troughed at $12.5 million in Q1 2023.
A 3-year average of $25.0 million and a median of $25.0 million in 2022 frame the typical range for Restructuring Costs.
The widest annual swing landed in 2023, when Restructuring Costs plunged 50.0%; it then surged 200.0% in 2024.
A 3-year view of Restructuring Costs shows it stood at $25.0 million in 2022, then jumped by 50.0% to $37.5 million in 2023, then plunged by 66.67% to $12.5 million in 2024.
Per Business Quant data, the three most recent Restructuring Costs figures were $12.5 million in Q3 2024, $37.5 million in Q2 2024, and $37.5 million in Q1 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	Krystal Biotech	9.83 Bn	8.99 Bn	112.79 Mn

Download Data